10.2337/db10-0128 Diabetes 33 HoltM
As with other incretin-based therapies, the most commonly reported adverse effects of retatrutide in clinical trials have been gastrointestinal in nature
Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety & efficacy of Retatrutide, a first-in-class GIP, GLP-1 & glucagon triple hormone receptor agonist, in adults with obesity or overweight & knee osteoarthritis
Disha Narang, an endocrinologist and director of obesity medicine at Endeavor Health in Chicago, who was not involved in the new research
[29] Those two novel peptides were later isolated, identified, and investigated by other researchers, and are now known as glucagon-like peptide-1 and glucagon-like peptide-2
As in any other liver diseases, multiple aetiologies of steatosis can coexist in the same individual and are likely associated with variations in natural history and therapeutic responses